Literature DB >> 25151994

Testosterone levels and clinical features of schizophrenia with emphasis on negative symptoms and aggression.

Mirna Sisek-Šprem1, Aida Križaj, Vlado Jukić, Milan Milošević, Zrinka Petrović, Miroslav Herceg.   

Abstract

BACKGROUND: Aggressive behavior and negative symptoms are two features of schizophrenia that may have a hormonal basis. AIM: The aim of this study was to compare testosterone level with clinical features of schizophrenia, focusing on negative symptoms and aggressive behavior.
METHODS: The study population consisted of 120 male schizophrenic patients (ages 18-40) classified into non-aggressive (n = 60) and aggressive (n = 60) groups. Depending on the type of aggression that was manifested prior to admission, the aggressive group was divided into violent (n = 32) and suicidal (n = 28) subgroups. Psychopathological severity, violence and suicidality were assessed using the Positive and Negative Syndrome Scale (PANSS), Overt Aggression Scale and Columbia Suicide Severity Rating Scale, respectively. Total serum testosterone level was determined on the same morning that symptoms were assessed.
RESULTS: In the non-aggressive group, testosterone level was negatively correlated with the score on the negative subscale of PANSS (P = 0.04) and depression (P = 0.013), and positively correlated with excitement (P = 0.027), hostility (P = 0.02) and impulsive behavior (P = 0.008). In the aggressive group, testosterone level had non-significant correlation with these parameters, and with violent or suicidal behavior.
CONCLUSIONS: The results confirmed that non-aggressive male schizophrenic patients with lower levels of testosterone had a greater severity of negative symptoms. In aggressive patients, there was no correlation between testosterone and clinical features of the disorder or the degree or type of aggression. These findings indicate that therapeutic strategies targeting testosterone could be useful in the treatment of negative symptoms of schizophrenia.

Entities:  

Keywords:  Aggressiveness; Clinical features; Negative symptoms; Schizophrenia; Testosterone

Mesh:

Substances:

Year:  2014        PMID: 25151994     DOI: 10.3109/08039488.2014.947320

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  6 in total

Review 1.  Sex differences in schizophrenia, bipolar disorder, and post-traumatic stress disorder: Are gonadal hormones the link?

Authors:  Andrea Gogos; Luke J Ney; Natasha Seymour; Tamsyn E Van Rheenen; Kim L Felmingham
Journal:  Br J Pharmacol       Date:  2019-03-14       Impact factor: 8.739

2.  Why sex differences in schizophrenia?

Authors:  Rena Li; Xin Ma; Gang Wang; Jian Yang; Chuanyue Wang
Journal:  J Transl Neurosci (Beijing)       Date:  2016-09

3.  Association of Negative Symptoms of Schizophrenia Assessed by the BNSS and SNS Scales With Neuropsychological Performance: A Gender Effect.

Authors:  Paweł Wójciak; Klaudia Domowicz; Marta Zabłocka; Michał Michalak; Janusz K Rybakowski
Journal:  Front Psychiatry       Date:  2021-12-24       Impact factor: 4.157

Review 4.  Do Sex/Gender and Menopause Influence the Psychopathology and Comorbidity Observed in Delusional Disorders?

Authors:  Alexandre González-Rodríguez; Mary V Seeman; Alexandre Díaz-Pons; Rosa Ayesa-Arriola; Mentxu Natividad; Eva Calvo; José A Monreal
Journal:  J Clin Med       Date:  2022-08-04       Impact factor: 4.964

5.  Relationship of Brain-Derived Neurotrophic Factor with Interleukin-23, Testosterone and Disease Severity in Schizophrenia.

Authors:  Priya Allimuthu; Hanumanthappa Nandeesha; Raghavi Chinniyappan; Balaji Bhardwaz; Jesudas Blessed Raj
Journal:  Indian J Clin Biochem       Date:  2020-03-14

6.  Biological Aspects of Aggression and Violence in Schizophrenia.

Authors:  WonKyung Cho; Won-Suk Shin; Iseul An; Minji Bang; Doo-Yeoun Cho; Sang-Hyuk Lee
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-11-20       Impact factor: 2.582

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.